Safety concerns on the development of novel therapeutic drugs.

about

What is the future of targeted therapy in rheumatology: biologics or small molecules?

P2860

Q35118364-16C5C9DF-0BE3-4574-B9DD-87EC0C4EA3F1

P2860

Safety concerns on the development of novel therapeutic drugs.

Item

http://www.wikidata.org/entity/Q42138494

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Safety concerns on the development of novel therapeutic drugs.

@en

Safety concerns on the development of novel therapeutic drugs.

@nl

type

Item

label

Safety concerns on the development of novel therapeutic drugs.

@en

Safety concerns on the development of novel therapeutic drugs.

@nl

prefLabel

Safety concerns on the development of novel therapeutic drugs.

@en

Safety concerns on the development of novel therapeutic drugs.

@nl

P1476

Safety concerns on the development of novel therapeutic drugs

@en

P2093

Steffen Gay

http://www.w3.org/2001/XMLSchema#string

P2860

Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis

Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies

Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.

Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo.

Gene analysis for exploring the effects of drugs in rheumatoid arthritis.

Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis.

Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.

P2888

ar2032

P304

112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2032

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Ospelt

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6821557

http://www.w3.org/2001/XMLSchema#string

P6179

1041462779

http://www.w3.org/2001/XMLSchema#string

P698

16968526

http://www.w3.org/2001/XMLSchema#string

P932

1779448

http://www.w3.org/2001/XMLSchema#string

Safety concerns on the development of novel therapeutic drugs.

about

P2860

P2860

Safety concerns on the development of novel therapeutic drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932